ANN ARBOR, Mich., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that it intends to offer to sell, subject to market and other conditions, units

ANN ARBOR, Mich., Dec. 21, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that shareholders of the Company approved all five proxy proposals at the Annual

ANN ARBOR, Mich., Dec. 9, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that the NASDAQ Hearings Panel (Panel) has granted the Company's request to

Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders Ann Arbor, MI, December 9, 2009 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fiscal Year 2009 Annual Meeting of Shareholders When: Monday, December 14, 2009 @

Physicians Present Continued Progress in Company's Vascular Clinical Program

National PI Presents Encouraging Progress in U.S. Cardiac Clinical Trial

Catheter-Based Delivery of CRCs by Cardiologists to Expand Company's Ongoing Cardiovascular Program

Focus on Cardiovascular Regeneration Sets Foundation for Continued Clinical Progress

Distinguished Cardiovascular and Thoracic Surgeon and Chair of Cardiovascular & Thoracic Surgical Research, Education & Clinical Excellence at Baylor University Medical Center to Strengthen Company's Board

Company Meets All Other NASDAQ Capital Market Initial Listing Requirements Other Than the $1.00 Minimum Bid Price Rule; Company Will Request Hearing to Present Plans for Regaining Compliance; Company to Remain Listed On NASDAQ Capital Market During Hearing Process